WXXWY News and Press, Wuxi Biologics Cayman Inc ADR From 04/21/20

SHANGHAI and LEVERKUSEN, Germany, April 22, 2020 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, announced that it has completed the acquisition deal with Bayer for a drug product manufacturing plant...

SUZHOU, China , April 14, 2020 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platform, announced that WuXi Biologics (Suzhou) Co., Ltd. has successfully passed its first GMP inspection by the European Medicines Agency...

Wuxi Biologics ADR ( OTCPK:WXXWY ): FY Non-GAAP EPS of RMB0.91; GAAP EPS of RMB0.76. More news on: Wuxi Biologics (Cayman) Inc ADR, WuXi Biologics (Cayman) Inc., Earnings news and commentary, , Read more ...

CHF Solutions (NASDAQ: CHFS )  announced the use of its Aquadex ultrafiltration therapy to treat volume overload in COVID-19 patients. Shares up  35%  premarket. More news on: CHF Solutions, Inc., Endonovo Therapeutics, Inc., Twist Bioscience Corporation, Healthcare stocks ...

DUNDALK, Ireland , March 11, 2020 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, announced that it has completed the weather-tig...

Vir Biotechnology ( VIR +27.6% ) jumps to all-time highs after announcing a development and manufacturing collaboration with WuXi Biologics ( OTCPK:WXXWY ) to advance and produce antibodies for a potential coronavirus treatment . More news on: Vir Biotechnology, Inc., Wuxi Biologics (Ca...

SAN FRANCISCO and SHANGHAI , Feb. 25, 2020 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, and Vir Biotechnology, Inc. ("Vir") ...

SHANGHAI , Feb. 24, 2020 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, congratulates its strategic partner Immutep, a biot...

SHANGHAI , Feb. 18, 2020 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, announced that WuXi Vaccines, its joint venture with Sha...

SHANGHAI , Feb. 18, 2020 /PRNewswire/ -- WuXi Vaccines, a new vaccine Contract Development and Manufacturing Organization (CDMO) established between WuXi Biologics (stock code: 2269.HK) and Shanghai Hile Bio-technology (stock code: 603718.SH) announced that it has entered into a strategic...